CD Bioparticles Launches Innovative Organoid Construct Kit to Advance Drug Discovery
CD Bioparticles launches Organoid Construct Kits to the scientific community to facilitate the construction of complex organoid models.
- (1888PressRelease) September 24, 2024 - CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its Organoid Construct Kits to the scientific community to facilitate the construction of complex organoid models, enabling researchers to advance drug discovery and development, disease modeling, and personalized medicine.
Organoids are microscopic organ-like structures derived from stem cells that have become powerful tools for studying disease mechanisms, drug efficacy and toxicity. CD Bioparticles now offers a variety of Organoid Construction Kits to simplify the process of generating organoids and enable scientists to accelerate their research. This comprehensive portfolio of Organoid Construction Kits includes Cervical Cancer Organoid Construct Kit, Gastric Cancer Organoid Construction Kit, Intestinal Organoid Construction Kit, Lung Cancer Organoid Construction Kit, and Ovarian Cancer Organoid Construction Kit.
These kits include a complete set of optimized reagents, protocols and technical support to guide users through the entire organoid construction process. For example, the ready-to-use Intestinal Organoid Construction Kit can maximize the the satisfaction of customer’s experimental needs, provide the greatest convenience, and reduce the time spent on non-experimental processes. The Organoid Construction Kit is divided into four modules: Part I: Tissue Dissociation and Organoid Construction; Part II: Organoid Transfer; Part III: Organoid Freezing; and Part IV: Organoid Recovery.
The products provide customers with consumables and reagents needed for the entire experimental process, saving time wasted in purchasing various reagents and consumables. Customers only need to equip the product with routine instruments and consumables to complete the entire experimental process of intestinal cancer organoid construction. With its user-friendly protocol and high-quality components, researchers can now streamline their organoid development process and achieve reproducible results.
The Organoid Construction Kit is the latest addition to CD Bioparticles’ extensive portfolio of drug delivery products and services. The company also offers a wide range of 3D cell culture substrates, engineered tissue scaffolds, and other biomaterials for various applications in drug delivery, diagnostics, and research. With these tools, the company can provide researchers with custom solution to the challenges they often face in creating optimal cell growth environments, acquiring sufficient lab materials, and developing biocompatible support structures for tissue regeneration.
In addition, CD Bioparticles offers specialized delivery techniques, tissue engineering scaffold design and modification, and advanced technology platforms to accelerate research. The new products reflect the company’s commitment to providing cutting-edge tools that support scientists in their endeavors to advance biomedical research and empower researchers to explore the complexities of human biology and develop novel therapeutic approaches.
CD Bioparticles is dedicated to delivering quality solutions to meet the evolving needs of the scientific community. For more information about the Organoid Construct Kits, please visit https://www.cd-bioparticles.net/medical-device.
About CD Bioparticles
CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam